• 100+

    The UK’s most active investor in UK university spin-outs

  • £250M

    Over £250m raised; invested into over 100 companies

  • 16 wins

    Award winning manager with track record of delivering returns

  • £1.2Bn

    Part of FTSE 250 sector specialist group with £1.2bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Olivia Goodchild
Gordon Lawson
Chloe Richardson
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Mind Foundry

Mind Foundry’s AI and Machine Learning platform will build the systems of intelligence that allow organisations to create new opportunities, optimise complex decisions and generate better outcomes. The platform allows organisations to leverage their existing investment in technology, future-proofing their business models with state-of-the-art operational machine learning helping them help them t

Symetrica

Symetrica specializes in the detection and identification of radioisotopes for Security Applications. The company works with prime contractors and government agencies to design, develop, test and deploy detection equipment for use by law enforcement personnel, customs officers, the emergency services, military personnel and first responders.

Creavo

Creavo has developed diagnostic technology using magnetocardiography (MCG) to measure fluctuations in magnetic fields caused by heart activity. The first product resulting from the work will help physicians in A&E departments rule out significant heart disease in patients presenting with chest pains. This represents a considerable portion of A&E patients but existing protocols take up

View Portfolio